2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134240
    L-Threonic acid magnesium 778571-57-6 ≥99.0%
    L-Threonic acid magnesium (Magnesium L-threonate) is the enantiomer of Threonic acid and the metabolite of vitamin C (HY-B0166). L-Threonic acid magnesium is a magnesium supplementation, that improves the brain magnesium concentration, inhibits the activation of TNF-α/NF-κB signaling pathway. L-Threonic acid magnesium can be used in research of Alzheimer’s disease. L-Threonic acid magnesium is orally active.
    L-Threonic acid magnesium
  • HY-P99014
    Cusatuzumab 1864871-20-4 98.87%
    Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML).
    Cusatuzumab
  • HY-W016814
    (Z)-Aconitic acid 585-84-2 99.28%
    (Z)-Aconitic acid is an orally active glutamate decarboxylase inhibitor. (Z)-Aconitic acid reduces IκB-α phosphorylation. (Z)-Aconitic acid inhibits Antigen-induced arthritis and Monosodium urate (HY-B2130A)-induced gout.
    (Z)-Aconitic acid
  • HY-10017
    SCH 546738 906805-42-3 98.71%
    SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.
    SCH 546738
  • HY-NP008
    β-Lactoglobulin 9045-23-2 98%
    β-Lactoglobulin, a major whey protein, is a small globular protein from the lipocalin family. β-Lactoglobulin is an important source of the essential and branched-chain amino acids (leucine, isoleucine, and valine). β-Lactoglobulin shows antioxidant properties, because it contains two disulfide bonds and one free thiol group. β-Lactoglobulin is a ligand transport agent. β-Lactoglobulin is one of the major allergens in milk and can be utilized in the research for developing safe hypoallergenic dairy products.
    β-Lactoglobulin
  • HY-13508
    JNJ-7777120 459168-41-3 99.95%
    JNJ-7777120 is a potent and selective histamine H4 receptor antagonist (Ki=4.5 nM). JNJ-7777120 effectively blocks histamine-induced migration of mouse tracheal mast cells from connective tissue to epithelial cells. JNJ-7777120 also significantly blocks neutrophil infiltration in a mouse Zymosan-induced peritonitis model. JNJ-7777120 has a good potential to study antipruritic and anti-inflammatory.
    JNJ-7777120
  • HY-10582
    Flurbiprofen 5104-49-4 99.95%
    Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer.
    Flurbiprofen
  • HY-19562
    PF-06260933 1811510-56-1 99.39%
    PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
    PF-06260933
  • HY-100619
    BMS-986020 1257213-50-5 99.91%
    BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
    BMS-986020
  • HY-N0893
    Tetrahydrocurcumin 36062-04-1 98.96%
    Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.
    Tetrahydrocurcumin
  • HY-P99053
    Tralokinumab 1044515-88-9 99.12%
    Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.
    Tralokinumab
  • HY-P99446
    Atacicept 845264-92-8 99.84%
    Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease.
    Atacicept
  • HY-76711
    Naltrexone 16590-41-3 99.94%
    Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone
  • HY-A0103
    Xanthan gum 11138-66-2
    Xanthan gum interacts with gelatin (HY-Y1365) via hydrogen bonds, thereby increasing the viscosity and stability of the hydrogel while promoting cell growth and creating a microenvironment conducive to cell differentiation[1][2]. Xanthan gum induces pro-inflammatory responses by increasing the levels of TNF-α, IL-6, and IL-10. Xanthan gum can be used for inflammation and immunology research.
    Xanthan gum
  • HY-N1178
    Taraxasterol 1059-14-9 ≥98.0%
    Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases.
    Taraxasterol
  • HY-NP004
    Cobra Venom Factor
    Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
    Cobra Venom Factor
  • HY-Y0262
    Oxalic acid, 99% 144-62-7
    Oxalic acid, 99% (Ethanedioic acid) is a dicarboxylic acid found in a wide variety of plants. Oxalic acid, 99% shows antioxidant acyivity and suppresses lipid peroxidation. Oxalic acid, 99% is a pathogenicity factor for sclerotinia sclerotiorum, and suppresses the oxidative burst of the host plant. Oxalic acid, 99% exerts acaricidal activity. Oxalic acid can be used for the researches of sclerotinia disease, varroatosis and inflammatory diseases.
    Oxalic acid, 99%
  • HY-107427
    PF-3644022 1276121-88-0 ≥99.0%
    PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC50s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect.
    PF-3644022
  • HY-113227
    Oxoadipic acid 3184-35-8 99.86%
    Oxoadipic acid is a key intermediate metabolite in the lysine degradation pathway. The level of Oxoadipic acid is significantly negatively correlated with the abundance of Staphylococcus. That is, the higher the abundance of Staphylococcus-a potential pathogenic bacterium that usually increases in ulcerative colitis-the lower the level of Oxoadipic acid. Oxoadipic acid can be used in the research of ulcerative colitis.
    Oxoadipic acid
  • HY-119970
    Helenalin 6754-13-8 99.92%
    Helenalin is an anti-inflammatory sesquiterpene lactone. Helenalin selectively inhibits transcription factor NF-κB by directly targeting p65. Helenalin has alkylating activity, targets the cysteine sulfhydryl groups in the p65 subunit of NF-κB, thereby inhibits its DNA binding.
    Helenalin
Cat. No. Product Name / Synonyms Application Reactivity